ArticleTherapeutic advances in medical oncology2025
Weight change and BMI are not prognostic markers of survival outcomes in sacituzumab govitecan therapy for mTNBC in the Polish female cohort.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Understanding the mechanisms underlying obesity induced tumorigenesis: therapeutic perspectives to manage dysregulated lipid metabolism.Discover oncology · 2026Review
- Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe.The oncologist · 2026Article
- Antibody-drug conjugates in breast oncology: new standards, emerging challenges, and future directions.Therapeutic advances in medical oncology · 2026Article
- Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety.Cancer chemotherapy and pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Body mass index (BMI) and weight change are commonly explored as prognostic factors in breast cancer. However, their impact on outcomes with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC) remains poorly defined. Objectives: To evaluate the association between baseline BMI, weight change during treatment, and clinical outcomes-including survival and adverse events (AEs)-in a real-world Polish cohort of women with mTNBC receiving SG therapy. Design: A retrospective, multicenter cohort study. Methods: A total of 83 women with mTNBC treated with SG across four oncology centers in Poland between August 2021 and September 2024 were analyzed. BMI was categorized by World Health Organization (WHO) criteria: underweight (BMI < 18.5 kg/m Results: The mPFS was 4.07 months (95% CI: 3.05-6.18), and the mOS was 8.01 months (95% CI: 6.05-9.75). The median follow-up time was 7.42 months (95% CI: 6.07-8.96). Neither baseline BMI nor weight change significantly influenced PFS (BMI Conclusion: In this real-world Polish cohort of women with mTNBC treated with SG, neither BMI nor weight changes were prognostic indicators for survival or AE profiles. These findings underscore the necessity for identifying more reliable prognostic biomarkers in this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.